<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01007175</url>
  </required_header>
  <id_info>
    <org_study_id>3242K1-2001</org_study_id>
    <secondary_id>B2271004</secondary_id>
    <nct_id>NCT01007175</nct_id>
  </id_info>
  <brief_title>Study Evaluating Multiple Ascending Doses Of ATN-103 In Japanese Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Clinical Efficacy Of ATN-103 Administered To Japanese Subjects With Active Rheumatoid Arthritis On A Background Of Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ablynx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ablynx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This primary purpose of this study is to evaluate the safety, tolerability, and&#xD;
      pharmacokinetic properties of multiple ascending doses of ATN-103 administered subcutaneously&#xD;
      (below the skin) to Japanese subjects with active rheumatoid arthritis and on a stable&#xD;
      background of methotrexate. Some subjects will receive ATN-103 while other subjects will&#xD;
      receive a placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability will be evaluated on the basis of AEs, SAEs,(including injection site reactions and infections), physical examination findings, vital sign, measurements, immunogenicity assessments, early termination, and clinical laboratory test.</measure>
    <time_frame>20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy for Rheumatoid Arthritis (RA) based on ACR responses, ACR-N, DAS 28 and EULAR response.</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATN-103 10 mg q4wks</intervention_name>
    <description>ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATN-103 30 mg q4wks</intervention_name>
    <description>ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.3 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATN-103 80 mg q4wks</intervention_name>
    <description>ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATN-103 10 mg q8wks</intervention_name>
    <description>ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATN-103 80 mg q8wks</intervention_name>
    <description>ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meets the ACR 1987 revised criteria for classification of Rheumatoid Arthritis (RA).&#xD;
&#xD;
          -  ACR functional class I through III.&#xD;
&#xD;
          -  Active RA at the time of screening and at baseline consisting of = 6 swollen and = 6&#xD;
             tender joints at least.&#xD;
&#xD;
          -  hs-CRP level = 8 mg/L.&#xD;
&#xD;
          -  Must be receiving MTX for at least 12 wks, with a stable dose and route of MTX for at&#xD;
             least 6 wks prior to the baseline and continuing on that dose for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  The report of a chest x-ray performed within 12 wks before the screening documenting&#xD;
             the absence of any evidence of malignancy, infection, or abnormalities suggestive of&#xD;
             TB must be obtained and available in the subject's study file prior to baseline.&#xD;
&#xD;
          -  All WOCBP must have a negative pregnancy test result at screening and baseline.&#xD;
&#xD;
          -  All WOCBP who have sexual intercourse with a nonsurgically sterilized male partner&#xD;
             must agree and commit to the use of the following highly effective forms of&#xD;
             contraception for the duration of the study and for 8 wks after the last dose of&#xD;
             investigational product.&#xD;
&#xD;
          -  All male subjects who are biologically capable of fathering children must agree and&#xD;
             commit to the use of a reliable method of birth control for the duration of the study&#xD;
             and for 8 wks after the last dose of investigational product.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Presence of active infections or open cutaneous ulcers or any underlying disease that&#xD;
             could predispose subjects to infections or history of serious infection within 4 wks&#xD;
             before the baseline.&#xD;
&#xD;
          -  A history or current evidence of latent or active TB, evidence of prior or currently&#xD;
             active TB by chest X-ray, recent close contact with an individual with active TB, or a&#xD;
             positive Mantoux tuberculin skin test.&#xD;
&#xD;
          -  Other significant concurrent medical conditions at the time of the screening or&#xD;
             baseline.&#xD;
&#xD;
          -  Laboratory abnormalities at screening. Positive for HBsAg, HBcAb, and/or HepCAb.&#xD;
             ALTand/or AST= 2 times the ULN or higher. Hemoglobin = 8.5 g/dL or lower. Platelet =&#xD;
             125,000 /mm³ or lower, or = 1,000,000 /mm³ or higher. WBC = 3500 /mm³ or lower. Serum&#xD;
             creatinine= 2 mg/dL or higher.&#xD;
&#xD;
          -  Any prior use of B cell-depleting therapy.&#xD;
&#xD;
          -  Receipt within 24 wks before the baseline visit:&#xD;
&#xD;
        Any cytotoxic drugs. Leflunomide. Any investigational biological drug(s).&#xD;
&#xD;
          -  Receipt within 12 wks before the baseline visit: Any biological drugs not listed under&#xD;
             the exclusion criteria. Any surgical joint interventions (open or arthroscopic). Any&#xD;
             investigational drugs (other than investigational biological drugs), procedures, or&#xD;
             devices.&#xD;
&#xD;
          -  Receipt within 8 wks before the baseline: Abatacept. Any type of TNF inhibitors not&#xD;
             listed under the exclusion criteria.&#xD;
&#xD;
          -  Receipt within 4 wks before the baseline: Any DMARDs, other than stable background&#xD;
             MTX, or immunosuppressive drugs not listed under the exclusion criteria.&#xD;
&#xD;
          -  Etanercept. IA hyaluronic acid injections. Any live (attenuated) vaccine.&#xD;
&#xD;
          -  Receipt within 2 wks before the baseline: &gt; 10 mg/day of oral prednisone or&#xD;
             equivalent, or change in the dose of oral prednisone or its equivalent.&#xD;
&#xD;
          -  IA, bolus IM, or IV treatment with corticosteroids. &gt; 1 NSAID, change of dose of the&#xD;
             NSAID, or NSAID use greater than the maximum recommended dose.&#xD;
&#xD;
          -  Initiation of statins or dosage adjustment to a current statin. Change in the dose of&#xD;
             folic acid.&#xD;
&#xD;
          -  Known or suspected allergy to ATN-103, any type of TNF inhibitors, human&#xD;
             immunoglobulin proteins, or other compounds related to these classes of medication.&#xD;
&#xD;
          -  Current or history of psychiatric disease or alcohol or drug abuse that, in the&#xD;
             opinion of the investigator, would interfere with the ability to comply with the study&#xD;
             protocol or give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josefin-Beate Holz</last_name>
    <role>Study Director</role>
    <affiliation>Ablynx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Saga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 2, 2009</study_first_submitted>
  <study_first_submitted_qc>November 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2009</study_first_posted>
  <last_update_submitted>September 3, 2013</last_update_submitted>
  <last_update_submitted_qc>September 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TNF inhibitor</keyword>
  <keyword>Multiple ascending dose study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

